CClinicalTrials.gg
RecruitingNCT07273058Updated Dec 9, 2025

Effect of HIIT on Post-Stroke Fatigue

An interventional study of HIIT and MICT in Stroke, sponsored by The Hong Kong Polytechnic University. Recruiting at 1 site in Hong Kong. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

This study aims to investigate the effect of high-intensity interval training (HIIT) on fatigue severity among individuals with chronic stroke. Participants will be randomly assigned to the HIIT group, the moderate-intensity continuous training (MICT) group, or the stretching group (active control). Each group will participate in supervised exercise sessions three times per week over a 12-week period, totaling 36 sessions. Outcome assessments will be conducted at baseline, mid-intervention (week 6), post-intervention (week 12), and follow-up (week 20). The primary outcome will be fatigue severity. Secondary outcomes will include inflammatory biomarkers and additional health-related indicators.

02

Conditions studied

  • Stroke

Browse trials for

03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's planned enrollment of 60 is above the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

The Hong Kong Polytechnic University is the lead sponsor of 659 studies on the registry; 250 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age of 40-80 years;
  • a history of ischemic stroke resulting in unilateral limb impairment 6-60 months prior to consent to participate in the pilot trial;
  • a stable medical condition;
  • a subjective feeling of fatigue, defined as a period of apparent fatigue, decreased energy, increased need for rest, or fatigue out of proportion to physical activity for at least 2 weeks during the past month;
  • ability to communicate with the investigators and lack of significant cognitive deficits;
  • able to walk for 10 meters with or without a walking aid.

Exclusion criteria

Exclusion criteria:

  • An FSS score of \< 4 (20);
  • other neurological conditions;
  • other musculoskeletal comorbidities that would prevent safe participation in exercises;
  • a medical diagnosis of significant cardiovascular, pulmonary, or metabolic disease(s);
  • signs or symptoms indicative of significant cardiovascular, pulmonary, or metabolic disease(s) during the previous 3 months;
  • severe lower limb spasticity (Ashworth Scale score ≥ 3);
  • Botulinum toxin use in the affected lower limb within the past six months;
  • current or previous use of drugs intended to resolve post-stroke fatigue;
  • active engagement in other stroke rehabilitation trials.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    HIIT

    Behavioral: HIIT

  • Active comparator
    MICT

    Behavioral: MICT

  • Active comparator
    Stretching

    Behavioral: stretching

Interventions

  • BehavioralHIIT

    The HIIT intervention will consist of a 3-minute warm-up, a 25-minute main exercise, and a 2-minute cool-down. The main exercise will include four 4-minute high-intensity intervals, each interspersed with a 3-minute low-intensity recovery period. Participants will attend three supervised sessions per week over a 12-week period.

  • BehavioralMICT

    The MICT intervention will include a 3-minute warm-up, 25 minutes of continuous exercise performed at a moderate intensity, and a 2-minute cool-down. Participants will attend three supervised sessions per week over a 12-week period.

  • Behavioralstretching

    The stretching intervention will consist of 30 minutes of whole-body stretching. Participants will attend three sessions per week over a 12-week period.

06

What researchers measure

Primary outcomes

  1. Eligibility rate (%)

    Time frame: Through study completion, an average of 12 weeks.

  2. Recruitment rate (number of participants per month)

    Time frame: Through study completion, an average of 12 weeks.

  3. Compliance with HIIT (%)

    Time frame: From baseline to week 12

  4. Fidelity to the HIIT protocol (%)

    Time frame: From baseline to week 12

  5. Retention of the intervention (%)

    Time frame: From baseline to week 12

  6. Adverse events (number of events)

    Time frame: From baseline to week 12

  7. Acceptability (qualitative)

    Time frame: At week 12

Secondary outcomes

  1. Fatigue Severity Scale (FSS)

    The FSS consists of 9 items rated on a 7-point Likert scale from 1 (highly disagree) to 7 (highly agree). Higher scores indicate greater fatigue severity.

    Time frame: Blinded assessors will conduct evaluations at baseline, week 12 , and week 20.

  2. Multidimensional Fatigue Inventory (MDI)

    The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report questionnaire designed to assess fatigue across five dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation, and Reduced Activity. Each subscale contains 4 items rated on a 5-point Likert scale. Higher scores indicate greater fatigue. The total score ranges from 20 to 100.

    Time frame: Blinded assessors will conduct evaluations at baseline, week 12 , and week 20.

  3. Short Form-36 Health Survey (SF-36)

    The SF-36 includes 36 items and one additional item assessing perceived change in health over time. Each domain is scored on a scale from 0 to 100, with higher scores indicating better health status.

    Time frame: Blinded assessors will conduct evaluations at baseline, week 6, and week 12.

  4. Inflammatory biomarkers

    Inflammatory biomarkers will be quantified using enzyme-linked immunosorbent assay (ELISA) kits obtained from commercial suppliers, following the manufacturer's instructions.

    Time frame: Blinded assessors will conduct evaluations at baseline, week 6, and week 12.

Other outcomes

  1. Hospital Anxiety and Depression Scale (HADS)

    The HADS consists of 14 items, divided into two subscales: anxiety (HADS-A) and depression (HADS-D), each containing 7 items. Each item is scored on a 4-point Likert scale (0-3), resulting in subscale scores ranging from 0 to 21. Higher scores indicate greater severity of anxiety or depression.

    Time frame: Blinded assessors will conduct evaluations at baseline, week 12 , and week 20.

  2. Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is consists of 19 items grouped into seven components. Each component is scored from 0 to 3, yielding a global score ranging from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: Blinded assessors will conduct evaluations at baseline, week 12 , and week 20.

  3. Stroke Self-Efficacy Questionnaire (SSEQ)

    The SSEQ is a 13-item self-report scale assessing stroke survivors' confidence in performing daily activities and managing post-stroke challenges. Each item is rated from 0 (not at all confident) to 4 (very confident). Total score ranges from 0 to 52. Higher scores indicate greater self-efficacy.

    Time frame: Blinded assessors will conduct evaluations at baseline, week 12 , and week 20.

  4. Fugl-Meyer Motor Assessment-Lower Extremity

    To assess motor recovery, Fugl-Meyer Motor Assessment-Lower Extremity will be used, it score rangefrom 0 to 34; a high score is indicative of good motor recovery

    Time frame: Blinded assessors will conduct evaluations at baseline, week 12 , and week 20.

  5. 6-Minute Walk Test

    Walking endurance will be assessed using the 6-Minute Walk Test. The participants will be allowed to use assistive devices, which will be documented and kept consistent across all of the time points.

    Time frame: Blinded assessors will conduct evaluations at baseline, week 12 , and week 20.

  6. Physical Activity Enjoyment Scale (PAES)

    The PAES will be used to measure the participants' exercise enjoyment (score range: 0-56). A high score indicates a high level of activity enjoyment.

    Time frame: Blinded assessors will conduct evaluations at week 6 and at week 12.

  7. Behavioral Regulation In Exercise Questionnaire (BREQ-2)

    The BREQ-2 includes 19 items. Each item is rated on a 5-point Likert scale ranging from 0 ("not true for me") to 4 ("very true for me"). Higher scores reflect higher exercise motivation.

    Time frame: Blinded assessors will conduct evaluations at week 1, week 12, and week 20.

  8. Mini Balance Evaluation Systems Test (MiniBEST)

    The Mini-BESTest consists of 14 items, including the Timed Up and Go test, with a maximum total score of 28 points. Higher scores indicate better balance performance.

    Time frame: Blinded assessors will conduct evaluations at baseline, week 12 , and week 20.

  9. Short Physical Performance Battery (SPPB)

    The SPPB comprises three components: balance tests (including side-by-side, semi-tandem, and tandem stances), a gait speed test, and a five-times sit-to-stand test. Each component is scored on a scale from 0 to 4, with a total possible score ranging from 0 to 12. Higher scores indicate better physical performance.

    Time frame: Blinded assessors will conduct evaluations at baseline, week 12 , and week 20.

07

Study locations

1 of 1 sites recruiting
  • The Hong Kong Polytechnic University
    Kowloon, Hong Kong
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07273058
Lead sponsor
The Hong Kong Polytechnic University
Responsible party
Dr HUANG Mei Zhen (Assistant professor, The Hong Kong Polytechnic University) — Principal investigator
First posted
Dec 9, 2025
Start date
Oct 15, 2025
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Dec 9, 2025

Study contacts

Mei Zhen Prof. Huang
Contact
mei-zhen.huang@polyu.edu.hk
+852 00000000
Fong Sze Chung
Contact
fschung@polyu.edu.hk

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion